---
title: Hippotherapy improves balance and mobility
nct_id: NCT06500182
phase: NA
status: RECRUITING
sponsor: Central Hospital Saint Quentin
study_type: INTERVENTIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT06500182"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06500182"
last_fetched: "2026-05-10T14:06:00.016Z"
source: "Parkinson's Pathways (curated)"
---
# Hippotherapy improves balance and mobility

**Goal (in five words):** Hippotherapy improves balance and mobility

**Official Title:** The Benefits of Hippotherapy for Patients With Parkinson's Disease of 75 Years of Age or More at Risk of Losing Their Independance.

**Trial ID:** [NCT06500182](https://clinicaltrials.gov/study/NCT06500182)

## Key Facts

- **Phase:** NA
- **Status:** RECRUITING
- **Study Type:** INTERVENTIONAL
- **Sponsor:** Central Hospital Saint Quentin
- **Target Enrollment:** 36 participants
- **Start Date:** 2023-07-01
- **Completion Date:** 2024-07
- **Conditions:** Parkinson Disease
- **Interventions:** hippotherapy sessions
- **Intervention Types:** OTHER

## Summary For Families

A program of therapeutic horse riding uses the horse’s gentle, rhythmic movement to stimulate balance, posture and gait, with the goal of helping people 75 and older with Parkinson’s keep or slow the loss of independence. The sessions are given in addition to usual Parkinson’s medications, so hippotherapy is intended to complement levodopa or other drugs by improving motor control and mobility rather than replacing medication. The study is looking for people aged 75 or over with Parkinson’s who can give informed consent, have preserved autonomy and no major cognitive or behavioral problems, are not under guardianship, and have no contraindication to MRI or to participating in horse riding.

## Eligibility

- **Minimum age:** 75 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

* Age ≥ 75 years with PD according to Movement Disorders Society criteria (2015).
* Clinical diagnosis of Alzheimer's disease
* Has been on stable antiparkinsonian treatment for less than 3 months.
* Ability to understand the principle of the study as well as its risks.
* Written consent to participate in the trial.
* Have social insurance
* Agree to comply with all safety procedures during the study and its duration.
* Ability to understand and freely give consent
* Patient affiliated to social security or entitled beneficiary
* Autonomy preserved

Exclusion criteria :

* age \<75 years
* refusal to sign consent
* MOCA \<23
* Presence of major behavioural problems that do not allow MRI to be performed under optimal conditions
* Subjects unable to receive informed information, unable to participate in the study as a whole
* Subjects with a diagnosis of atypical parkinsonian syndrome (Lewy body disease, progressive supranuclear palsy, multisystem atrophy, cortico-basal degeneration, etc.).
* A classic contraindication to an MRI examination: claustrophobia, presence of incompatible foreign material,
* Subjects who have practised horse riding at a high level, animal phobias, wish to stop studying, etc.
* No affiliation to a social security scheme
* Antiparkinsonian treatment has not been stable for at least 3 months.
* People under protective supervision (guardianship, curatorship)
* People under family guardianship are also excluded, as are people for whom a mandate for future protection has been activated.
```

## Locations (1)

- Centre Hospitalier de Saint-Quentin;, Saint-Quentin, Aisne, France _(49.8489, 3.2876)_
  - ATTIER Dr Jadwiga, PI — (CONTACT)

## Central Contacts

- Jadwiga ATTIER, PHD — (CONTACT) — 0323065707 — a.attier@ch-stquentin.fr
- Abdelkrim BOULANOUAR, M — (CONTACT) — 03323067861 — a.boulanouar@ch-stquentin.fr

---

*Canonical: https://parkinsonspathways.com/trial/NCT06500182*  
*HTML version: https://parkinsonspathways.com/trial/NCT06500182*  
*Source data: https://clinicaltrials.gov/study/NCT06500182*